Abstract
Neurodegenerative disorders such as Alzheimers and Parkinsons diseases are characterized by distinct clinical manifestations and neuropathological hallmarks, but they also share common features like mitochondrial dysfunction. As strategic organelles in several cellular pathways, including life/death decision, it is crucial to maintain a healthy mitochondrial pool to ensure cellular homeostasis. Macroautophagy is a pathway of lysosomal-dependent degradation of cytosolic portions, such as misfolded proteins or damaged organelles. In the last decade this process has gained new frontiers and is currently seen as a specific, rather than a random process. In this regard the term mitophagy came to describe the selective degradation of mitochondria by autophagy. This review is intended to discuss mitochondrial dysfunction in Alzheimers and Parkinsons diseases. The recent developments on the molecular basis of mitophagy will be also argued. Finally, we will discuss mitophagy as a potential therapeutic target for neurodegenerative diseases.
Keywords: Mitochondrial dysfunction, Alzheimer's disease, Parkinson's disease, mitophagy, potential therapy, neurodegeneration, oxidative injury, ROS, autophagy, pathophysiology
Current Drug Targets
Title: Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Volume: 12 Issue: 6
Author(s): R. X. Santos, S. C. Correia, C. Carvalho, S. Cardoso, M. S. Santos and P. I. Moreira
Affiliation:
Keywords: Mitochondrial dysfunction, Alzheimer's disease, Parkinson's disease, mitophagy, potential therapy, neurodegeneration, oxidative injury, ROS, autophagy, pathophysiology
Abstract: Neurodegenerative disorders such as Alzheimers and Parkinsons diseases are characterized by distinct clinical manifestations and neuropathological hallmarks, but they also share common features like mitochondrial dysfunction. As strategic organelles in several cellular pathways, including life/death decision, it is crucial to maintain a healthy mitochondrial pool to ensure cellular homeostasis. Macroautophagy is a pathway of lysosomal-dependent degradation of cytosolic portions, such as misfolded proteins or damaged organelles. In the last decade this process has gained new frontiers and is currently seen as a specific, rather than a random process. In this regard the term mitophagy came to describe the selective degradation of mitochondria by autophagy. This review is intended to discuss mitochondrial dysfunction in Alzheimers and Parkinsons diseases. The recent developments on the molecular basis of mitophagy will be also argued. Finally, we will discuss mitophagy as a potential therapeutic target for neurodegenerative diseases.
Export Options
About this article
Cite this article as:
X. Santos R., C. Correia S., Carvalho C., Cardoso S., S. Santos M. and I. Moreira P., Mitophagy in Neurodegeneration: An Opportunity for Therapy?, Current Drug Targets 2011; 12 (6) . https://dx.doi.org/10.2174/138945011795528813
DOI https://dx.doi.org/10.2174/138945011795528813 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AMPK and its Activator Berberine in the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Putative Molecular Interactions Involving Naturally Occurring Steroidal Alkaloids from Sarcococca hookeriana Against Acetyl- and Butyryl- Cholinesterase
Current Bioinformatics Synthesis, In vitro and In silico Evaluation of a Series of Pyrazolines as New Anticholinesterase Agents
Letters in Drug Design & Discovery Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry The Proinflammatory Cytokine GITRL Contributes to TRAIL-mediated Neurotoxicity in the HCN-2 Human Neuronal Cell Line
Current Alzheimer Research Microarray RNA/DNA in Different Stem Cell Lines
Current Pharmaceutical Biotechnology Machine Learning and Molecular Dynamics Based Insights into Mode of Actions of Insulin Degrading Enzyme Modulators
Combinatorial Chemistry & High Throughput Screening Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Aqueous Extract of <i>Cola nitida</i> and <i>Garcinia kola</i> Synergistically Enhances Hippocampal-hypothalamic Glutamate and Na+ /K+ -ATPase Activity in Male Wistar Rats
Current Drug Discovery Technologies Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Allosteric Modulation of Muscarinic Acetylcholine Receptors
Current Neuropharmacology Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings
Current Molecular Pharmacology Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine